Diagnostic Work-Up and Initial Management for Suspected SLE
Immediately refer the patient to secondary or tertiary care for specialist evaluation, prioritizing as a 3-week wait target if there is strong clinical suspicion of SLE. 1
Diagnostic Approach
Serological Testing Algorithm
When clinical suspicion exists, proceed with the following laboratory evaluation:
Initial screening:
- ANA testing - Only perform when reasonable clinical suspicion exists. ANAs are present in 95-99% of SLE patients, so a negative test makes SLE unlikely (though results can fluctuate). 1
Confirmatory panel (if ANA positive):
- Anti-dsDNA antibodies - Highly supportive of SLE diagnosis 1
- Extractable nuclear antigen (ENA) antibodies - Including anti-Smith (Sm) antibody, which is highly specific for SLE 1
- C3/C4 complement levels - Low levels support SLE diagnosis 1
- Antiphospholipid antibodies (aPL) and lupus anticoagulant (LAC) - Test at diagnosis in all suspected cases; positive results require confirmation on two occasions at least 12 weeks apart 1
Critical caveat: Classification criteria (SLICC 2012 or EULAR/ACR 2019) may be used as a guide but not as diagnostic criteria. 1 Diagnosis requires a combination of clinical, laboratory, and immunological features attributable to SLE, made by clinicians experienced in its management. 1
Special Consideration for Pediatric Patients
In children and young people with symptoms suggestive of SLE but negative ANA, consider monogenic lupus and complement deficiencies. 1
Initial Assessment Once Diagnosis Suspected
Multi-System Evaluation
Assess for manifestations across all organ systems:
- Renal: Urinalysis and blood pressure at every visit 1
- Hematologic: Complete blood count
- Musculoskeletal: Joint involvement patterns
- Mucocutaneous: Rashes, photosensitivity, oral ulcers
- Cardiopulmonary: Serositis, pulmonary involvement
- Neuropsychiatric: Cognitive dysfunction, seizures, psychosis
Determine whether clinical manifestations are due to disease activity, damage, drug toxicity, infection, thrombosis, or comorbidities. 1
Disease Activity Measurement
Use validated disease activity tools such as BILAG-2004 or SLEDAI-2K to categorize disease as absent, mild, moderate, or severe. 1
Initial Management Principles
Foundation Therapy
Hydroxychloroquine (HCQ) is recommended for all patients with SLE unless contraindicated, at a dose not exceeding 5 mg/kg real body weight. 2 This is first-line therapy regardless of disease severity.
Ophthalmological screening: Perform at baseline, after 5 years, then yearly thereafter (in absence of risk factors for retinal toxicity). 2
Glucocorticoid Strategy
- Doses and route depend on organ involvement severity 2
- Intravenous methylprednisolone pulses (250-1000 mg/day for 1-3 days) provide immediate effect and enable lower starting oral doses 2
- Target: Minimize chronic maintenance to <7.5 mg/day prednisone equivalent 2
- When possible, withdraw completely 2
Treatment Goals
Aim for remission or low disease activity with prevention of flares in all organs, maintained with the lowest possible glucocorticoid dose. 2 This treat-to-target approach prioritizes long-term survival, prevention of organ damage, and optimization of quality of life.
Referral Urgency Rationale
The 3-week wait target for strong suspicion cases is critical because delayed diagnosis leads to increased disease activity, organ damage, and significantly impaired quality of life and long-term health outcomes. 1 Studies show mean time from initial symptoms to diagnosis averages 6.4 years, with 47% of patients initially misdiagnosed. 1 Early symptoms are often non-specific, and cardinal features may not be present initially but accumulate over time.
Important distinction: "Strong suspicion" is uncommon among ANA-positive referrals—only a minority warrant this prioritization. 1